|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021469,
umls-concept:C0205314,
umls-concept:C0206492,
umls-concept:C0271510,
umls-concept:C0302350,
umls-concept:C0542341,
umls-concept:C0597357,
umls-concept:C0679622,
umls-concept:C1155003,
umls-concept:C1414554,
umls-concept:C2587213
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2010-7-12
|
|
pubmed:abstractText |
To exploit the physiologic Fcgamma receptor IIb (CD32B) inhibitory coupling mechanism to control B cell activation by constructing a novel bispecific diabody scaffold, termed a dual-affinity retargeting (DART) molecule, for therapeutic applications.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Bispecific,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigen-Antibody Complex,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD79,
http://linkedlifedata.com/resource/pubmed/chemical/Fc gamma receptor IIB,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulins,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, IgG
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1529-0131
|
|
pubmed:author |
pubmed-author:BonviniEzioE,
pubmed-author:BurkeStephenS,
pubmed-author:CiccaroneValentinaV,
pubmed-author:FryDD,
pubmed-author:GorlatovSergeyS,
pubmed-author:HuangLingL,
pubmed-author:JinLindaL,
pubmed-author:JohnsonSydS,
pubmed-author:KoenigScottS,
pubmed-author:MinorTamaraT,
pubmed-author:MoorePaul APA,
pubmed-author:QuonC YCY,
pubmed-author:RaineyG JonahGJ,
pubmed-author:TuaillonNadineN,
pubmed-author:VeriMaria-ConcettaMC,
pubmed-author:YiM QMQ,
pubmed-author:ZhangTengfeiT
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
62
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1933-43
|
|
pubmed:meshHeading |
pubmed-meshheading:20506263-Animals,
pubmed-meshheading:20506263-Antibodies, Bispecific,
pubmed-meshheading:20506263-Antibodies, Monoclonal,
pubmed-meshheading:20506263-Antigen-Antibody Complex,
pubmed-meshheading:20506263-Antigens, CD79,
pubmed-meshheading:20506263-Arthritis, Experimental,
pubmed-meshheading:20506263-B-Lymphocytes,
pubmed-meshheading:20506263-Cell Proliferation,
pubmed-meshheading:20506263-Cells, Cultured,
pubmed-meshheading:20506263-Dimerization,
pubmed-meshheading:20506263-Female,
pubmed-meshheading:20506263-Humans,
pubmed-meshheading:20506263-Immunoglobulins,
pubmed-meshheading:20506263-Immunosuppressive Agents,
pubmed-meshheading:20506263-Lymphocyte Activation,
pubmed-meshheading:20506263-Male,
pubmed-meshheading:20506263-Mice,
pubmed-meshheading:20506263-Mice, Knockout,
pubmed-meshheading:20506263-Receptors, IgG,
pubmed-meshheading:20506263-Signal Transduction,
pubmed-meshheading:20506263-Spleen,
pubmed-meshheading:20506263-Tissue Scaffolds
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold.
|
|
pubmed:affiliation |
MacroGenics, Inc., Rockville, Maryland 20850, USA.
|
|
pubmed:publicationType |
Journal Article
|
